Phase I/II trial of ischemia tolerant mesenchymal stem cells in patients with chronic heart failure.
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 May 2014
Price : $35 *
At a glance
- Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Stemedica Cell Technologies
- 13 May 2014 New trial record
- 29 May 2012 Mexico's regulatory agency, COFEPRIS, has approved the protocol of this trial, according to a Stemedica Cell Technologies media release.